Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IMVAMUNE in Atopic Dermatitis
NCT00316602Phase 2Completed
- Sponsor
- Bavarian Nordic
- Start
- Jul 2006
- Primary completion
- Nov 2009
- Modality
- Live Attenuated Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of JYNNEOS in smallpox, sponsored by Bavarian Nordic. Started Jul 2006; status: completed.
02
Drugs
JYNNEOS
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT00316602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00316602.